Trial Outcomes & Findings for Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation (NCT NCT02974686)
NCT ID: NCT02974686
Last Updated: 2020-08-10
Results Overview
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
TERMINATED
PHASE4
1 participants
3 months
2020-08-10
Participant Flow
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Participant milestones
| Measure |
Interventional Everolimus (EVR)
Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
Everolimus
|
Prior Agent Mycophenolic Acid (MPA)
Patient will have baseline data collected while on MPA for comparison with EVR
Mycophenolic Acid
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 3 monthsPopulation: Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1, 6, and 12 monthsPopulation: Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 12 monthsPopulation: Trial was terminated with only 1 participant enrolled, no data is reported to protect patient confidentiality
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Outcome measures
Outcome data not reported
Adverse Events
Interventional (EVR)
Prior Agent (MPA)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place